Zhejiang Jolly Pharmaceutical Co.,LTD (SHE:300181)
17.03
+0.03 (0.18%)
At close: Feb 3, 2026
SHE:300181 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 2,804 | 2,569 | 1,937 | 1,787 | 1,450 | 1,086 |
Other Revenue | 8.95 | 8.95 | 5.2 | 18.23 | 7.26 | 5.32 |
| 2,813 | 2,578 | 1,942 | 1,805 | 1,457 | 1,091 | |
Revenue Growth (YoY) | 11.51% | 32.71% | 7.61% | 23.86% | 33.60% | 19.72% |
Cost of Revenue | 1,099 | 1,019 | 616.36 | 534.65 | 420.35 | 362.9 |
Gross Profit | 1,713 | 1,559 | 1,326 | 1,271 | 1,037 | 727.98 |
Selling, General & Admin | 971.92 | 949.08 | 874.18 | 921.45 | 794.25 | 601.17 |
Research & Development | 62.96 | 71.94 | 79.38 | 64.43 | 45.63 | 30.39 |
Other Operating Expenses | -50.35 | -58.7 | -49.99 | -42.32 | -28.31 | -21.62 |
Operating Expenses | 990.28 | 968.57 | 904.42 | 948.8 | 812.78 | 610.52 |
Operating Income | 723.1 | 590.51 | 421.66 | 321.71 | 224.26 | 117.46 |
Interest Expense | -13.35 | -9.29 | -7.62 | -8.32 | -12.07 | -17.44 |
Interest & Investment Income | 6.53 | 15.95 | 22 | 4.64 | 4.41 | 2.05 |
Currency Exchange Gain (Loss) | 0 | 0 | 0 | -0 | - | - |
Other Non Operating Income (Expenses) | 1.68 | -0.47 | 0.18 | -0.01 | -1.13 | 1.65 |
EBT Excluding Unusual Items | 717.96 | 596.7 | 436.21 | 318.02 | 215.47 | 103.71 |
Gain (Loss) on Sale of Investments | -2.36 | -0.66 | -0.1 | 0.08 | 0.52 | 0.39 |
Gain (Loss) on Sale of Assets | 0.04 | 0.35 | 0.28 | -9.71 | -1.92 | -0.08 |
Asset Writedown | -11.33 | -8.06 | -0.53 | - | - | - |
Other Unusual Items | 8.36 | 8.36 | 10.78 | 15.74 | 8.24 | 5.17 |
Pretax Income | 712.67 | 596.69 | 446.64 | 324.12 | 222.31 | 109.18 |
Income Tax Expense | 105.98 | 80.73 | 55.88 | 38.6 | 30.33 | 13.87 |
Earnings From Continuing Operations | 606.69 | 515.96 | 390.76 | 285.52 | 191.98 | 95.31 |
Net Income to Company | 606.69 | 515.96 | 390.76 | 285.52 | 191.98 | 95.31 |
Minority Interest in Earnings | -10.42 | -8.19 | -7.83 | -12.51 | -12.58 | -6.51 |
Net Income | 596.27 | 507.77 | 382.94 | 273.01 | 179.41 | 88.8 |
Net Income to Common | 596.27 | 507.77 | 382.94 | 273.01 | 179.41 | 88.8 |
Net Income Growth | 15.21% | 32.60% | 40.27% | 52.17% | 102.03% | 246.98% |
Shares Outstanding (Basic) | 696 | 696 | 696 | 607 | 619 | 609 |
Shares Outstanding (Diluted) | 696 | 696 | 696 | 607 | 619 | 609 |
Shares Change (YoY) | 0.12% | -0.10% | 14.76% | -1.93% | 1.64% | 0.12% |
EPS (Basic) | 0.86 | 0.73 | 0.55 | 0.45 | 0.29 | 0.15 |
EPS (Diluted) | 0.86 | 0.73 | 0.55 | 0.45 | 0.29 | 0.15 |
EPS Growth | 15.07% | 32.73% | 22.22% | 55.17% | 98.77% | 246.56% |
Free Cash Flow | 28.3 | 34.16 | 156.75 | 140.56 | 103.84 | 221.34 |
Free Cash Flow Per Share | 0.04 | 0.05 | 0.23 | 0.23 | 0.17 | 0.36 |
Dividend Per Share | 0.600 | 0.600 | 0.450 | 0.300 | 0.200 | 0.100 |
Dividend Growth | 33.33% | 33.33% | 50.00% | 50.00% | 100.00% | 400.00% |
Gross Margin | 60.92% | 60.48% | 68.27% | 70.38% | 71.16% | 66.73% |
Operating Margin | 25.71% | 22.91% | 21.71% | 17.82% | 15.39% | 10.77% |
Profit Margin | 21.20% | 19.70% | 19.71% | 15.12% | 12.31% | 8.14% |
Free Cash Flow Margin | 1.01% | 1.32% | 8.07% | 7.79% | 7.12% | 20.29% |
EBITDA | 794.49 | 657.69 | 483.23 | 378.43 | 277.87 | 171.31 |
EBITDA Margin | 28.25% | 25.51% | 24.88% | 20.96% | 19.07% | 15.70% |
D&A For EBITDA | 71.38 | 67.18 | 61.58 | 56.72 | 53.61 | 53.85 |
EBIT | 723.1 | 590.51 | 421.66 | 321.71 | 224.26 | 117.46 |
EBIT Margin | 25.71% | 22.91% | 21.71% | 17.82% | 15.39% | 10.77% |
Effective Tax Rate | 14.87% | 13.53% | 12.51% | 11.91% | 13.64% | 12.71% |
Revenue as Reported | 2,813 | 2,578 | 1,942 | 1,805 | 1,457 | 1,091 |
Advertising Expenses | - | 28 | 15.71 | 675.37 | 528.45 | 377.85 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.